Medication undertreatment in assisted living settings.

BACKGROUND Residential care/assisted living (RC/AL) is a rapidly growing, long-term care setting, where medication use has not been carefully examined. We sought to determine the prevalence and predictors of nonprescribing of selected medications whose value in decreasing morbidity has been established in clinical trials. METHODS As part of a survey of a stratified random sample of 193 RC/AL facilities in Florida, Maryland, New Jersey, and North Carolina, data were gathered on 2014 residents 65 years and older. Patient characteristics and diagnoses were recorded based on medical record reviews and in-person patient assessments; all medications administered at least 4 of the previous 7 days were recorded. Data on facility characteristics were obtained by interviewing facility administrators. Bivariate and multivariate logistic regression was performed to identify associations between medication nonprescribing and facility characteristics, physician visitation, and patient age, sex, race, comorbidity, functional dependency, and cognition. RESULTS Of 328 subjects with congestive heart failure, 204 (62.2%) were not receiving an angiotensin-converting enzyme inhibitor; of 172 subjects with prior myocardial infarction, 60.5% were not receiving aspirin and 76.2% were not receiving beta-blockers; of 435 patients with history of stroke, 37.5% were not receiving an anticoagulant or antiplatelet agent; and of 315 patients with osteoporosis, 61.0% were not receiving calcium supplementation and 51.1% were not receiving any treatment for the condition. Resident age, race, sex, comorbidity, cognitive status, and dependency in activities of daily living were rarely associated with nonprescribing; in contrast, facility factors-particularly facility type and the frequency of physician visits-were somewhat more frequently associated with nonprescribing. CONCLUSIONS Undertreatment appears to be prevalent in RC/AL facilities. Since preserving independence is often a primary goal of care in these settings, more attention may need to be paid to the use of treatments that have been shown to reduce long-term morbidity.

[1]  Jaakko Tuomilehto,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002 .

[2]  J. Potter,et al.  Heart Failure: Evaluation and Treatment of Patient's with Left Ventricular Systolic Dysfunction , 1998, Journal of the American Geriatrics Society.

[3]  D W Bates,et al.  Incidence and preventability of adverse drug events in nursing homes. , 2000, The American journal of medicine.

[4]  Randall S Stafford,et al.  The underutilization of cardiac medications of proven benefit, 1990 to 2002. , 2003, Journal of the American College of Cardiology.

[5]  M. Beers,et al.  Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. , 1997, Archives of internal medicine.

[6]  Y. Stern,et al.  Mortality in patients with dementia after ischemic stroke , 2002, Neurology.

[7]  L. Lipsitz,et al.  Correlates and Management of Nonmalignant Pain in the Nursing Home , 1999, Journal of the American Geriatrics Society.

[8]  Guidelines for Medical Treatment for Stroke Prevention , 1994, Annals of Internal Medicine.

[9]  G P Samsa,et al.  Adverse Drug Events In High Risk Older Outpatients , 1997, Journal of the American Geriatrics Society.

[10]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[11]  V. Hasselblad,et al.  Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. , 1999, Archives of internal medicine.

[12]  J. Alpert,et al.  Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. , 1992, The American journal of medicine.

[13]  A. Hildreth,et al.  Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. , 1998, Respiratory medicine.

[14]  D. Brand,et al.  Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. , 1995, Journal of the American College of Cardiology.

[15]  V. Hachinski,et al.  Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. , 1997, Archives of neurology.

[16]  M. Paik,et al.  Treatment for the Secondary Prevention of Stroke in Older Patients: The Influence of Dementia Status , 1999, Journal of the American Geriatrics Society.

[17]  W. Aronow,et al.  Underutilization of Beta‐Blockers in Older Patients With Prior Myocardial Infarction or Coronary Artery Disease in an Academic, Hospital‐Based Geriatrics Practice , 1997, Journal of the American Geriatrics Society.

[18]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[19]  L. Lipsitz,et al.  Management of heart failure among very old persons living in long-term care: Has the voice of trials spread? , 2000 .

[20]  G. Lamas,et al.  Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. , 1999, Journal of the American Geriatrics Society.

[21]  D. Bates,et al.  Risk factors for adverse drug events among nursing home residents. , 2001, Archives of internal medicine.

[22]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[23]  P. Deedwania,et al.  Effects of Treatment on Outcome in Mildly Symptomatic Patients With Ischemia During Daily Life: The Atenolol Silent Ischemia Study (ASIST) , 1994, Circulation.

[24]  W. Thies,et al.  Fighting heart disease and stroke. Recommendations of the AHA Stroke Positioning Task Force. , 1998, Stroke.

[25]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[26]  J. Gurwitz,et al.  Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. , 2001, Archives of internal medicine.

[27]  H. Meyer The bottom line on assisted living. , 1998, Hospitals & health networks.

[28]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[29]  H. Meyer The right to appeal. , 1998, Hospitals & health networks.

[30]  F. Avanzini,et al.  Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators. , 1997, European heart journal.

[31]  M. Llorente,et al.  Inappropriate Medication Prescribing in Homebound Older Adults , 1999, Journal of the American Geriatrics Society.

[32]  B. Dawson-Hughes,et al.  A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women , 1991, The New England journal of medicine.

[33]  B. Henderson,et al.  Menopausal estrogen therapy and hip fractures. , 1982, Annals of internal medicine.

[34]  H. Krumholz,et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.

[35]  D. Himmelstein,et al.  Inappropriate drug prescribing for the community-dwelling elderly. , 1994, JAMA.

[36]  B. Zarowitz,et al.  The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction. , 1993, Progress in cardiovascular diseases.

[37]  Mark A. Hlatky,et al.  Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .

[38]  H. Genant,et al.  Long-term estrogen replacement therapy prevents bone loss and fractures. , 1985, Annals of internal medicine.

[39]  C. Gatsonis,et al.  Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. , 1998, JAMA.

[40]  K. Swedberg,et al.  Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. , 1996, The American journal of cardiology.

[41]  H. Morgenstern,et al.  Inappropriate Medication Prescribing in Skilled-Nursing Facilities , 1992, Annals of Internal Medicine.

[42]  S. Zimmerman,et al.  End‐of‐Life Care in Assisted Living and Related Residential Care Settings: Comparison with Nursing Homes , 2003, Journal of the American Geriatrics Society.

[43]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[44]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[45]  S. Zimmerman,et al.  Inappropriate Medication Prescribing in Residential Care/Assisted Living Facilities , 2002, Journal of the American Geriatrics Society.

[46]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[47]  J. Avorn,et al.  Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. , 1999, Journal of clinical epidemiology.

[48]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[49]  P. Rochon,et al.  Prescribing for seniors: neither too much nor too little. , 1999, JAMA.

[50]  D. Bates,et al.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.

[51]  N. Weiss,et al.  Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. , 1980, The New England journal of medicine.

[52]  D. Massel,et al.  Report of the Canadian Cardiovascular Society's consensus conference on the Management of the Postmyocardial Infarction Patient. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[53]  Jeffrey M. Hausdorff,et al.  Undertreatment of Cardiovascular Disease in Ethnically Diverse Older Adults: Who Should Receive an Electrocardiogram? , 2001, Journal of the American Geriatrics Society.

[54]  E. Antman,et al.  Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. , 1996, Archives of internal medicine.

[55]  K. Parker,et al.  Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. , 1998, Archives of internal medicine.

[56]  Estrogen Replacement Therapy and Fractures in Older Women , 1995 .

[57]  A. Wall,et al.  Book ReviewTo Err is Human: building a safer health system Kohn L T Corrigan J M Donaldson M S Washington DC USA: Institute of Medicine/National Academy Press ISBN 0 309 06837 1 $34.95 , 2000 .

[58]  C. Ambrose,et al.  Undertreatment of osteoporosis in men with hip fracture. , 2002, Archives of internal medicine.

[59]  J. Avorn,et al.  Epidemiology of Adverse Drug Events in the Nursing Home Setting , 1995, Drugs & aging.

[60]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[61]  Sidney C. Smith,et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[62]  J. Aloia,et al.  Calcium Supplementation with and without Hormone Replacement Therapy To Prevent Postmenopausal Bone Loss , 1994, Annals of Internal Medicine.

[63]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[64]  P. Sloane,et al.  The MDS Cognition Scale: A Valid Instrument for Identifying and Staging Nursing Home Residents with Dementia Using the Minimum Data Set , 1994, Journal of the American Geriatrics Society.

[65]  H. Perry,et al.  Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. , 2000, The American journal of medicine.

[66]  John C. Beck,et al.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. , 1991 .